Phraction Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Phraction Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$229K	Hold	367	–	–	0.04%	61
2026 Q1	$284K	Hold	367	–	–	0.06%	59
2025 Q4	$283K	Hold	367	–	–	0.08%	60
2025 Q3	$206K	Buy	+367	New	+$208K	0.06%	66
2025 Q2	–	Sell	-367	Closed	-$233K	–	81
2025 Q1	$233K	Hold	367	–	–	0.08%	69
2024 Q4	$261K	Hold	367	–	–	0.09%	63
2024 Q3	$386K	Hold	367	–	–	0.14%	54
2024 Q2	$386K	Hold	367	–	–	0.14%	52
2024 Q1	$353K	Hold	367	–	–	0.14%	52
2023 Q4	$322K	Hold	367	–	–	0.13%	47
2023 Q3	$302K	Hold	367	–	–	0.14%	46
2023 Q2	$264K	Sell	367 -95	-21%	-$73.2K	0.13%	43
2023 Q1	$380K	Sell	462 -90	-16%	-$67.9K	0.22%	40
2022 Q4	$398K	Hold	552	–	–	0.26%	35
2022 Q3	$380K	Buy	552 +50	+10%	+$31.5K	0.29%	41
2022 Q2	$297K	Buy	+502	New	+$326K	0.2%	57

Other funds holding REGN

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

AIP

ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return

HCM

Howland Capital Management Boston, Massachusetts $2.77B AUM 19.56% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Phraction Management's REGN Position: Q2 2026 in Review

Phraction Management held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 367 shares worth $229K. The position accounts for 0.04% of the portfolio, ranked #61.

Phraction Management first reported a position in REGN in Q2 2022 and has held it in 16 quarters since. The position peaked at $398K in Q4 2022. 228 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Phraction Management held 367 shares of Regeneron Pharmaceuticals worth $229K as of Q2 2026.
Phraction Management left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up 0.04% of Phraction Management's portfolio in Q2 2026, its #61 holding.
Phraction Management first reported a position in Regeneron Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
Phraction Management's Regeneron Pharmaceuticals position peaked at $398K in Q4 2022.
228 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Phraction Management's 13F filing for Q2 2026, filed 20 Jul 2026.